PITAVASTATIN TREATMENT ADVANTAGE IN CLINICAL PRACTICE

PITAVASTATIN TREATMENT ADVANTAGE IN CLINICAL PRACTICE

Authors

DOI:

https://doi.org/10.52340/jecm.2025.02.10

Keywords:

Pitavastatin, cardiovascular diseases, Pharmacology

Abstract

Cardiovascular diseases (CVDs) continue to represent the leading cause of mortality worldwide, predominantly driven by atherosclerosis. Key modifiable risk factors include dyslipidemia, hypertension, diabetes mellitus, tobacco use, physical inactivity, obesity, and psychosocial stress. Elevated LDL-C is recognized as a major contributor to the development of atherosclerotic cardiovascular disease (ASCVD), accounting for approximately 50% of attributable risk.

Pharmacological intervention, particularly the use of statins, is considered a cornerstone in the management of dyslipidemia. Statins function by competitively inhibiting (HMG-CoA) reductase, thereby reducing endogenous cholesterol synthesis in the liver. Statins have been shown to reduce LDL-C levels by 20-55%, elevate HDL-C by 5-15%, and lower triglyceride concentrations by 12-43%, depending on the agent and dosage employed. Total cholesterol levels may be decreased by 17-46%.

Decreased high-density lipoproteins and elevated triglycerides are independent risks for the development of coronary vascular disease. The treatment strategy should be directed not only to reduce the amount of LDL-C, but also to the correction of the amount of HDL-C and TG. From a group of well-known statins, pitavastatin should be noted due to its unique properties. Pitavastatin is a synthesized inhibitor of HMG-CoA reductase. Pitavastatin has a high ability to inhibit HMG-CoA reductase inhibitor. On the basis of studies conducted, it has been revealed that pitavastatin has a similar effect on atorvastatin and simvastatin in Japanese and Caucasian individuals, but additionaly, pitavastatin also has an effect of elevated HDL-C in long-term treatment.

One of the prominent and effective madications which contains pitavastatin on the Georgian market is Livazo. Livazo reduces LDL-C, total cholesterol levels, triglycerides levels, and also increases HDL-C.

Pitavastatin quickly absorbs from the upper gastrointestinal tract and reaches peak of concentrations in plasma within an hour of oral administration of the drug. Pitavastatin is quickly eliminated in bile, but enterohepatic recirculation, prolongs its action. Therefore, highly effective statins at low doses are quite effectively able to achieve the target dose of LDL-C. Medications, which have pleotropic effect, which have HDL-C increasing effect, also decreasing effect of total cholesterol and triglycerides, are well-known as more effective. Studies currently show that pitavastatin has a significant impact on the treatment of dyslipidemia and the reduction of the risks of cardiovascular disease in general.

Downloads

Download data is not yet available.

References

World Health Organization (2010) Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Available at: www.who.int/diabetes/publications/en/ (accessed May 2010).

O'Donnell M.J., Xavier D., Liu L., Zhang H., Chin S.L., Rao-Melacini P., et al. (2010) Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 376: 112–123

Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. (2007) European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 14(Suppl 2): S1–113

Grundy S.M., Cleeman J.I., Merz C.N., et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239

Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364: 937–952

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 106: 3143–3421

Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493): 1267–1278

LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435

Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361: 1149–1158

ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 288: 2998–3000

Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7–22

Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349–1357

Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301–1307

Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 106: 3143–3421

Kotseva K., Wood D., De Backer G., De Bacquer D., Pyörälä K., Keil U. (2009) EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Lancet 373: 929–940

Waters D.D., Brotons C., Chiang C.W., Ferrières J., Foody J., Jukema J.W., et al. (2009) Lipid treatment assessment project 2: A multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120: 28–34

Packard C.J., Ford I., Robertson M., Shepherd J., Blauw G.J., Murphy M.B., et al. (2005) Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 112: 3058–3065

Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Jr, Kastelein J.J., et al. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 373: 1175–1182

Crouse J.R., 3rd, Raichlen J.S., Riley W.A., Evans G.W., Palmer M.K., O'Leary D.H., et al. (2007) Effect of rosuvastatin on progression of carotid intimamedia thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA 297: 1344–1353

de Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A., White H.D., et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292: 1307–1316

Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., et al. (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 295: 1556–1565

Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., et al. (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291: 1071–1080

Pasterkamp G., Schoneveld A.H., van der Wal A.C., Hijnen D.J., et al. (1999) Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. Arterioscler Thromb Vasc Biol 19: 54–58

Little W.C. (1990) Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol 66: 44G–47G

Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357: 1301–1310

Giroud D., Li J.M., Urban P., Meier B., Rutishauer W. (1992) Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 69: 729–732

Yamazaki H., Fujino H., Kanazawa M. (2004) Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet). [In Japanese] Folia Pharmacol Jpn 123: 349–362

Ose L., Budinski D., Hounslow N.J., Arneson V. (2010) Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 210: 202–208

Saito Y. (2009) Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Man 5: 921–936

Morikawa S., Umetani M., Nakagawa S., Yamazaki H., Suganami H., Inoue K., et al. (2000) Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 7: 138–144

Aoki T., Nishimura H., Nakagawa S., Kojima J., Suzuki H., Tamaki T., et al. (1997) Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 47: 904–909

Ose L., Budinski D., Hounslow N.J., Arneson V. (2010) Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 210: 202–208

Shitara Y., Sugiyama Y. (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112: 71–105

Saito Y., Yamada N., Teramoto T., et al. (2002) Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 52: 251–255

Mukhtar R.Y., Reid J., Reckless J.P. (2005) Pitavastatin. Int J Clin Pract 59: 239–252

Fujino H., Saito T., Tsunenari Y., Kojima J., Sakaeda T. (2004) Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 34: 961–971

Fujino H., Yamada I., Shimada S., Yoneda M., Kojima J. (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 33: 27–41

Pitavatstatin Prescribing Information (2010) Kowa Pharmaceuticals, America. www.kowapharma.com/documents/LIVALOpitavastatinprescribinginformationV1_220100131.pdf (accessed September 2010).

Hayashi T., Yokote K., Saito Y., Iguchi A. (2007) Pitavastatin: Efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother 8: 2315–2327

Saito Y. (2009) Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Man 5: 921–936

Saito Y., Yamada N., Teramoto T., et al. (2002) Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 52: 251–255

Hounslow N.J., Budinski D., Eriksson M. (2010) Pitavastatin 4 mg shows comparable LDL-cholesterol and superior triglyceride reduction to simvastatin 40 mg in high risk primary hypercholesterolemia or combined dyslipidaemia. EAS 2010: Abstract 890.

Watson K.E. (2010) Pitavastatin: The newest HMG-CoA reductase inhibitor. Rev Cardiovasc Med 11: 26–32

Budinski D., Arneson V., Hounslow N., Gratsiansky N. (2009) Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 4: 291–302

Ose L., Budinski D., Hounslow N.J., Arneson V. (2010) Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 210: 202–208

Stender S., Hounslow N. (2009) Robust efficacy of pitavastatin and comparable safety to pravastatin. Atheroscler Suppl 10: P770

Kurihara Y., Douzono T., Kawakita K., Nagasaka Y. (2008) A large-scale, long-term prospective post-marketing surveillance of piavastatin (Livalo) — Livalo effectiveness and safety study (LIVES). Jpn Pharmacol Ther 36: 709–731

Yokote K., Bujo H., Hanaoka H., Shinomiya M., Miyashita Y., Nishikawa T., et al. (2008) Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atheroscler 201: 345–352

Shalev V., Chodick G., Silber H., Kokia E., Jan J., Heymann A.D. (2009) Continuation of statin treatment and all-cause mortality: A population-based cohort study. Arch Intern Med 169: 260–268

Meade L.T. (2007) Barriers to achieving LDL cholesterol goals. US Pharm 32: 66–71

Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493): 1267–1278

Hounslow N.J., Budinski D., Eriksson M. (2010) Pitavastatin 4 mg shows comparable LDL-cholesterol and superior triglyceride reduction to simvastatin 40 mg in high risk primary hypercholesterolemia or combined dyslipidaemia. EAS 2010: Abstract 890.

Hiro T., Kimura T., Morimoto T., Miyauchi K., Nakagawa Y., Yamagishi M., et al. (2009) Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54: 293–302

Teramoto T., Sasaki J., Ueshima H., Egusa G., Kinoshita M., Shimamoto K., et al. (2007) Executive summary of Japan Atherosclerosis Society JAS guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14: 45–50

Motomura T., Okamoto M., Kitamura T., Yamamoto H., Otsuki M., Asanuma N., et al. (2009) Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb 16: 546–552

Koshiyama H., Taniguchi A., Tanaka K., Kagimoto S., Fujioka Y., Hirata K., et al. (2008) Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. J Atheroscler Thromb 15: 345–350

Inoue K., Sugiyama A., Reid P.C., Ito Y., Miyauchi K., Mukai S., et al. (2007) Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27: 161–167

Sagara N., Kawaji T., Takano A., Inomata Y., Inatani M., Fukushima M., et al. (2007) Effect of pitavastatin on experimental choroidal neovascularization in rats. Exp Eye Res 84: 1074–1080

Kawakami A., Tani M., Chiba T., Yui K., Shinozaki S., Nakajima K., et al. (2005) Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol 25: 424–429

Kibayashi E., Urakaze M., Kobashi C., Kishida M., Takata M., Sato A., et al. (2005) Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci (Lond) 108: 515–521

Han J., Zhou X., Yokoyama T., et al. (2004) Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 109: 790–796

Hiraoka M., Nitta N., Nagai M., Shimokado K., Yoshida M. (2004) MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Life Sci 75: 1333–1341

Hiraoka M., Yoshida M. (2003) A novel HMG-CoA reductase inhibitor, pitavastatin inhibits IL-6-induced CRP in liver cells via ERK1/2-dependent but not STAT3-dependent signaling transduction. Circ J 67(Suppl 1): 271

Morikawa S., Takabe W., Mataki C., Kanke T., Itoh T., Wada Y., et al. (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9: 178–183

Morikawa S., Takabe W., Mataki C., Wada Y., Izumi A., Saito Y., et al. (2004) Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 11: 62–72

Hiraoka M., Yoshida M. (2003) A novel HMG-CoA reductase inhibitor, pitavastatin inhibits IL-6-induced CRP in liver cells via ERK1/2-dependent but not STAT3-dependent signaling transduction. Circ J 67(Suppl 1): 271

Markle R.A., Han J., Summers B.D., Yokoyama T., et al. (2003) Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem 90: 23–32

Suzuki H., Kobayashi H., Sato F., Yonemitsu Y., Nakashima Y., Sueishi K. (2003) Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 10: 109–116

Downloads

Published

2025-05-25

How to Cite

ZUBIASHVILI, M., KAKAURIDZE, N., MACHAVARIANI, P., & ZUBIASHVILI, T. (2025). PITAVASTATIN TREATMENT ADVANTAGE IN CLINICAL PRACTICE. Experimental and Clinical Medicine Georgia, (2), 44–58. https://doi.org/10.52340/jecm.2025.02.10

Issue

Section

Articles

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Loading...